Application of Neuroprotective Beta Amyloid Core Peptides and Peptidomimetic Derivatives to the Treatment of Alzheimer's DiseaseTechnology #ua17-050
Questions about this technology? Ask a Technology Manager
Title: Application of Neuroprotective Beta Amyloid Core Peptide and Peptidomimetic Derivatives to the Treatment of Alzheimer’s Disease
Invention: The present invention is a 6-peptide sequence and a peptidomimetic capable of suppressing the production of beta-amyloid and the aggregation and beta-amyloid into plaques. This technology mimics the smallest beta-amyloid peptide sequence necessary to prevent formation of beta-amyloid plaques and limit levels in the cerebrospinal fluid (CSF).
Background: Beta-amyloid aggregation is strongly linked with the development of Alzheimer’s disease and is cytotoxic in high concentrations. Lowering levels of beta-amyloid in the CSF as well as preventing the formation of beta-amyloid plaques can prevent Alzheimer’s disease as well as slow the progression of the disease in patients already afflicted. There are currently a number of large pharmaceutical companies focusing on the beta-amyloid pathway as a treatment for Alzheimer’s. Most drugs in the pipeline now are monoclonal antibodies, which rely on generating an immune response to lower levels of beta-amyloid in the CSF.
- Prevention and treatment of Alzheimer’s
- Offers the smallest necessary peptide sequence
- Preventative and therapeutic
- Does not rely on creating an immune response